Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - RA
 More »

  • AbbVie Expands Galapagos Collaboration to Include Crohn's Disease
    of GLPG0634 beyond rheumatoid arthritis (RA), for which the companies are about to ... will start early next year, and take place at the same time as the Phase IIb RA trial. ...
    5-17-2013
  • Bayer Prostate Cancer Drug Gains FDA Approval
    Bayer HealthCare said yesterday it is weeks away from joining Algeta in bringing to the U.S. market their advanced prostate cancer drug Xofigo® (radium Ra 223 dichloride) ...
    5-16-2013
  • Study: Protein Secreted by Certain Fat Cells Can Trigger RA
    messenger RNA for the RA-associated protein profactor D (pro-FD) in its mouse model study. ... Based on his team's discovery of pro-factor D in mice with RA, Banda and his colleagues ...
    5-8-2013
  • Biomarkers Take Center Stage
    ... including rheumatoid arthritis (RA), Crohn's disease, and psoriasis, among others. ... drugs)-naïve RA (rheumatoid arthritis) vs. knee OA (osteoarthritis) patient cohorts. ...
    5-1-2013
  • Biosimilars: 10 Drugs to Watch
    ... U.S. study recruiting participants as of April 17, according to ClinicalTrials.gov (NCT01682512) Celltrion and Hospira: Conducting Phase I trial in South Korea of CT-P10 for RA and ...
    4-22-2013
  • Biosimilars: Not So Far So Fast
    ... NHL, Merck with MK8808 in RA patients, as well as South Korean Celltrion in a joint venture with Hospira, testing CT-P10 in a Phase I trial for RA and another Phase I for lymphoma. ...
    3-15-2013
  • Receptos Licenses AbbVie Antibody for Co-Development
    ... The AbbVie immunology pipeline also includes two Phase II drug candidates-BT-061 for rheumatoid arthritis (RA) and psoriasis, and GLPG0634, also for RA. AbbVie completed a ...
    3-13-2013
  • Merck Doubles Lycera Bet to $600M+
    psoriasis, and rheumatoid arthritis (RA). "There are substantial unmet medical ... holds only North American rights, and the RA drug, MK-8457. Merck's need to boost its ...
    2-12-2013
  • Top 10 VC & Biopharma Equity Deals of 2012
    Series D financing Participating firms: ARCH Venture Partners, Forbion Capital Partners, RA Capital Management, Third Rock Ventures, TVM Capital, and two undisclosed investors 4 ...
    2-8-2013
  • Lilly Ends Phase III Rheumatoid Arthritis Program
    tabalumab for rheumatoid arthritis (RA), ending three Phase III trials of the drug ... the first quarter of 2013 toward ending the RA program for tabalumab, one of the company's ...
    2-7-2013
  • Janssen Pharmaceutica Pays Galapagos $5.3M
    novel small molecule therapeutics for the treatment of rheumatoid arthritis (RA), under which Janssen may select up to 12 programs from Galapagos' internally identified RA targets. ...
    1-16-2013
  • Galapagos Deals Aim to Shore Up Drug Discovery
    ... of JAK1, for rheumatoid arthritis (RA) and potentially other inflammatory diseases. ... successful completion of the RA Phase II studies that meet undisclosed preagreed criteria. ...
    1-15-2013
  • Top 20 Venture Capital Firms
    ... Principia, Promedior Pharmaceuticals, Ra Pharmaceuticals, Replidyne, Ribozyme ... Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm, Roka Bioscience, Satori ...
    12-17-2012
  • Advertorial: Quantifying Low-Abundance TH17 Cytokines to Uncover...
    Figure 1 Figure 1. Case Study: RA vs. Healthy. A multimarker analysis of rheumatoid arthritis patients (RA) vs. age-gender matched healthy volunteers (HV) was conducted using the ...
    12-1-2012
  • Incyte Wins $50M from Lilly as RA Drug Enters Phase III
    initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, ... with moderate-to-severe RA who had an inadequate response to treatment with methotrexate. ...
    11-15-2012
  • More »

    Journal Articles

  • Cyp26b1 Mediates Differential Neurogenicity in Axial-Specific...
    Carly Leung, Sherwin Chun Leung Chan, Sze Lan Tsang, Wutian Wu, Mai Har Sham
    Stem Cells and Development
    the neurogenic responses of adult SCPCs to retinoic acid (RA), an essential factor for adult neurogenesis. Although RA is a potent inducer of neuronal differentiation, we found ...
  • Increased Levels of FoxA1 Transcription Factor in Pluripotent...
    Yongjun Tan, Zhongqiu Xie, Miao Ding, Zhendong Wang, Qiqi Yu, Lei Meng, Hong Zhu, Xiaoqin Huang, Li Yu, Xiangxian Meng, Yan Chen
    Stem Cells and Development
    and is activated during retinoic acid (RA)-induced neural differentiation of ... During RA-induced P19 cell differentiation, elevated levels of FoxA1 increase the ...
  • Agathisflavone Enhances Retinoic Acid-Induced Neurogenesis and...
    Bruna S. Paulsen, Cleide S. Souza, Leonardo Chicaybam, Martin Hernán Bonamino, Marcus Bahia, Silvia Lima Costa, Helena L. Borges, Stevens K. Rehen
    Stem Cells and Development
    Here, we tested the hypothesis that neurogenesis induced by all-trans retinoic acid (RA) ... (EBs) for 4 days were treated with FAB (60?µM) and/or RA (2?µM) for additional 4 days. ...
  • Recombinant Human Thyrotropin in Thyroid Remnant Ablation with...
    Pedro Weslley Rosario, Arthur Cezar Malard Xavier, Maria Regina Calsolari
    Thyroid
    thyroidectomy followed by remnant ablation (RA) with 131I. There are less data regarding ... patients at high risk of relapse for RA. Methods: Post-thyroidectomy patients with ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll